Skip to search formSkip to main contentSkip to account menu

Ursodiol

Known as: Acid, Ursodeoxycholic, 3 alpha,7 beta Dihydroxy 5 beta cholan 24 oic Acid, (3?,5?,7?)-3,7-dihydroxycholan-24-oic acid 
A synthetically-derived form of ursodiol, a bile acid produced by the liver and secreted and stored in the gallbladder. Also produced by the Chinese… 
National Institutes of Health

Related topics

Related topics

42 relations

Narrower (25)

23-methylursodeoxycholic acid24-norursodeoxycholic acid3,6-dihydroxy-6-methylcholanoic acid6-fluoro-ursodeoxycholic acid
Expand
Bile Acids and SaltsBiliary cirrhosisCholelithiasisDrug Allergy
Expand

Broader (2)

Cholagogues and CholereticsUrsodeoxycholate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
Chemical Chaperones Reduce ER Stress and Restore Glucose Homeostasis in a Mouse Model of Type 2 Diabetes
Endoplasmic reticulum (ER) stress is a key link between obesity, insulin resistance, and type 2 diabetes. Here, we provide… 
Review
2004
Review
2004
[Primary sclerosing cholangitis].
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease, characterized by fibrosing inflammation and… 
Review
2004
Review
2004
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial
No effective medical therapy is available for all patients with nonalcoholic steatohepatitis (NASH). Ursodeoxycholic acid (UDCA… 
Review
2002
Review
2002
Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited
Ursodeoxycholic acid (UCDA) is increasingly used for the treatment of cholestatic liver diseases. Experimental evidence suggests… 
Highly Cited
2001
Highly Cited
2001
Ursodiol Use Is Associated with Lower Prevalence of Colonic Neoplasia in Patients with Ulcerative Colitis and Primary Sclerosing Cholangitis
Patients with ulcerative colitis have an increased risk for colorectal neoplasia; this risk approaches 0.5% to 1% per year of… 
Highly Cited
2000
Highly Cited
2000
American Association for the Study of Liver Diseases
  • P. Rosenthal
  • IDrugs : the investigational drugs journal
  • 2000
  • Corpus ID: 30831878
The latest advances in hepatology were presented in oral and poster presentations. In order to cover the varying subspecialties… 
Review
1999
Review
1999
The continuing importance of bile acids in liver and intestinal disease.
  • A. Hofmann
  • Archives of internal medicine
  • 1999
  • Corpus ID: 21211064
Bile acids, the water-soluble, amphipathic end products of cholesterol metabolism, are involved in liver, biliary, and intestinal… 
Highly Cited
1997
Highly Cited
1997
Ursodiol for Primary Sclerosing Cholangitis
Background There is no satisfactory medical therapy for patients with primary sclerosing cholangitis. Ursodiol (ursodeoxycholic… 
Highly Cited
1994
Highly Cited
1994
Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group.
BACKGROUND Ursodiol (ursodeoxycholic acid) therapy leads to major improvements in patients with primary biliary cirrhosis. The… 
Highly Cited
1991
Highly Cited
1991
A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group.
BACKGROUND In primary biliary cirrhosis the hepatic lesions may result, at least in part, from the intracellular accumulation of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License